Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Plug Power Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Plug Power Inc trades at $1.43 (market cap $2.18B). The key difference: Dyne Therapeutics Inc. Common Stock is the larger of the two by market cap, and Plug Power Inc is more actively traded (58,569,311 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Plug Power Inc for 42 Days on average.
| DYN | PLUG | |
|---|---|---|
Market Cap | $2.86B | $2.18B |
Volume | 3,341,579 | 58,569,311 |
Sector | Health | Industrials |
52-Week High | $26.78 | $4.14 |
52-Week Low | $14.60 | $1.45 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $2.18B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Plug Power (PLUG) trades at $1.45, down 10.49% today, reflecting ongoing operational challenges. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal persistent losses with a -220.59% net income margin and negative cash flow. Recent news highlights strategic partnerships including a 280 MW electrolyzer agreement with Arcadia eFuels, but the company continues to miss earnings expectations consistently.
Despite analyst consensus favoring Buy ratings (44.73%), PLUG faces significant execution risks with negative profitability and high cash burn. The $3.33 price target suggests potential upside if green hydrogen adoption accelerates, but investors must weigh substantial operational losses against long-term growth prospects in the clean energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
